INMED PHARMACEUTICALS INC. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
INMED PHARMACEUTICALS INC. (INM) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $12.62 thousand as of 2026-03-31, per its S-4 filed 2026-07-02.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-07-02
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $12.62K.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $19.44K.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $28.02K.
- 2025-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $47.05K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-03-31 | $12.62K S-4 · filed 2026-07-02 |
| 2025-12-31 | $19.44K 10-Q · filed 2026-02-11 |
| 2025-09-30 | $28.02K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $47.05K S-4 · filed 2026-07-02 |
| 2025-03-31 | $50.01K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $63.61K 10-Q · filed 2025-02-12 |
| 2024-09-30 | $84.08K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $82.21K 10-K · filed 2024-09-30 |
| 2023-09-30 | $4.76K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $2.02K 10-K · filed 2023-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |